Free Trial

Krystal Biotech (KRYS) News Today

$182.56
+0.60 (+0.33%)
(As of 12:57 PM ET)
Braidwell LP Has $24.34 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)
Braidwell LP boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 153.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 196,200 shares of the company's stock after buying an additional 118,703 sh
Eventide Asset Management LLC Invests $16.93 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)
Eventide Asset Management LLC acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 136,485 shares of the company's sto
Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the transaction, the insider now owns 1,525,882 shares of the company's stock, valued at approximately $268,189,020.32. The sale was disclosed in a document filed with the SEC, which is available at this link.
16,086 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Purchased by Superstring Capital Management LP
Superstring Capital Management LP bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 16,086 shares of the company's stock, valued at approximately $1,996,000.
Krystal Biotech (NASDAQ:KRYS) Shares Gap Up to $164.42
Krystal Biotech (NASDAQ:KRYS) Shares Gap Up to $164.42
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by TD Asset Management Inc
TD Asset Management Inc increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 82.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,962 shares of the company's stock after purchas
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Cut by Affinity Asset Advisors LLC
Affinity Asset Advisors LLC lowered its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 56.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 25,000 shares of the company's stock after selling 32,500 shares during the period. Affin
Decheng Capital LLC Takes $8.16 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)
Decheng Capital LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 65,772 shares of the company's stock, valued at a
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 550,806 shares of the company's stock after buy
Charles Schwab Investment Management Inc. Buys 5,258 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)
Charles Schwab Investment Management Inc. increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 185,038 shares of the company's
Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Director Sells 20,000 Shares of Stock
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) Director Julian S. Gangolli sold 20,000 shares of the business's stock in a transaction on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by BNP Paribas Financial Markets
BNP Paribas Financial Markets grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 34.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,072 shares of the company's stock after purchasing
Fiera Capital Corp Purchases Shares of 15,900 Krystal Biotech, Inc. (NASDAQ:KRYS)
Fiera Capital Corp purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 15,900 shares of the company's stock, valued at approximately $1,973,000. Fiera Capital
Nicholas Investment Partners LP Has $6.09 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)
Nicholas Investment Partners LP lowered its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 86.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,073 shares of the
Russell Investments Group Ltd. Sells 13,219 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)
Russell Investments Group Ltd. reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 34.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,479 shares of the company's stock after selling 13,21
FY2024 EPS Estimates for Krystal Biotech, Inc. Increased by Cantor Fitzgerald (NASDAQ:KRYS)
Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of Krystal Biotech in a report issued on Tuesday, May 7th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn $4.00 per shar
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Victory Capital Management Inc.
Victory Capital Management Inc. reduced its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 17.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 172,879 shares of the company's stock after selling 36,608 share
Q3 2024 EPS Estimates for Krystal Biotech, Inc. Lifted by Analyst (NASDAQ:KRYS)
Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Investment analysts at William Blair boosted their Q3 2024 EPS estimates for shares of Krystal Biotech in a research note issued to investors on Monday, May 6th. William Blair analyst T. Lugo now expects that the company will earn $0.63 per shar
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by New York State Common Retirement Fund
New York State Common Retirement Fund lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 32.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,993 shares of the company's stock after sellin
TimesSquare Capital Management LLC Buys 127,435 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)
TimesSquare Capital Management LLC grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 103.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,470 shares of the company's st
HC Wainwright Brokers Raise Earnings Estimates for Krystal Biotech, Inc. (NASDAQ:KRYS)
Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at HC Wainwright upped their Q2 2024 EPS estimates for Krystal Biotech in a report issued on Monday, May 6th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.37 for the quarter, up fr
Krystal Biotech (NASDAQ:KRYS) Announces Quarterly Earnings Results
Krystal Biotech (NASDAQ:KRYS - Get Free Report) posted its earnings results on Monday. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million during the quarter, compared to analysts' expectations of $47.37 million. Krystal Biotech's revenue for the quarter was up 452400.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.76) EPS.
Krystal Biotech (NASDAQ:KRYS) Shares Gap Down to $161.10
Krystal Biotech (NASDAQ:KRYS) Shares Gap Down to $161.10
Krystal Biotech (NASDAQ:KRYS) Earns "Buy" Rating from HC Wainwright
HC Wainwright restated a "buy" rating and issued a $200.00 target price on shares of Krystal Biotech in a research note on Monday.
Handelsbanken Fonder AB Has $15.28 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)
Handelsbanken Fonder AB increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,200 shares of the company's stock after purchasing an ad
Jennison Associates LLC Buys 383,495 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)
Jennison Associates LLC increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 112.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 724,344 shares of the company's stock after purchasin
Krystal Biotech (NASDAQ:KRYS) Receives Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $200.00 target price on shares of Krystal Biotech in a report on Monday.

KRYS Media Mentions By Week

KRYS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KRYS
News Sentiment

1.31

0.87

Average
Medical
News Sentiment

KRYS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KRYS Articles
This Week

9

4

KRYS Articles
Average Week

Get Krystal Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:KRYS) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners